Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;12(11):12425-12437.
doi: 10.1002/cam4.5952. Epub 2023 Apr 19.

Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis

Yohei Asano  1 , Norio Yamamoto  1 , Satoru Demura  1 , Katsuhiro Hayashi  1 , Akihiko Takeuchi  1 , Satoshi Kato  1 , Shinji Miwa  1 , Kentaro Igarashi  1 , Takashi Higuchi  1 , Yuta Taniguchi  1 , Sei Morinaga  1 , Takashi Sone  2   3 , Miho Okuda  4 , Isao Matsumoto  5 , Seiji Yano  2 , Hiroyuki Tsuchiya  1
Affiliations

Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis

Yohei Asano et al. Cancer Med. 2023 Jun.

Abstract

Backgrounds: Immune checkpoint inhibitors (ICIs) can significantly prolong the survival of patients with advanced non-small-cell lung cancer (NSCLC); however, few studies on the therapeutic effects of ICIs on bone metastases were performed.

Methods: This retrospective study aimed to investigate the therapeutic effects of ICIs and determine predictors of favorable ICI response and prognosis in 55 advanced NSCLC patients with bone metastases who initiated ICI treatment between 2016 and 2019, with a mean follow-up period of 23.2 months. Patients were classified into responders (complete or partial response) and non-responders (stable or progressive disease) according to the MD Anderson Cancer Center (MDA) criteria, and the predictors of therapeutic response were identified using multivariate logistic regression analysis. Furthermore, overall survival from the time of ICI administration to the final follow-up or death was evaluated, and prognostic predictors were identified using Cox proportional hazards regression analysis.

Results: ICI response rate was 30.9% (complete in three cases, partial in 14). Median survival time was 9.3 months, with 1-year and 2-year survival rates of 40.6% and 19.3%, respectively. Responders survived significantly longer than non-responders (p = 0.03). Based on the receiver operating characteristic curve, the predictive cutoff value of the pretreatment neutrophil-to-lymphocyte ratio (NLR) was 2.1. Multivariate analysis identified female sex (p = 0.03), use of ICIs as first-line therapy (p < 0.01), and NLR <2.1 (p = 0.03) as significant predictors of therapeutic response, whereas concomitant use of a bone-modifying agent (p < 0.01), Katagiri score ≤6 points (p < 0.01), and NLR <2.1 (p = 0.02) were identified as significant predictors of good prognosis.

Conclusions: This study identified some novel predictors for favorable therapeutic response and prognosis in advanced NSCLC patients with bone metastases undergoing ICI treatment. Pretreatment NLR less than 2.1 can be considered the most important predictor.

Keywords: bone metastasis; denosumab; immune checkpoint inhibitor; neutrophil-to-lymphocyte ratio; non-small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Overall survival rates of all patients, responders (CR + PR), and non‐responders (SD + PD).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394‐424. - PubMed
    1. Zhang N, Jiang J, Tang S, Sun G. Predictive value of neutrophil‐lymphocyte ratio and platelet‐lymphocyte ratio in non‐small cell lung cancer patients treated with immune checkpoint inhibitors: a meta‐analysis. Int Immunopharmacol. 2020;85:106677. - PubMed
    1. Moro‐Sibilot D, Smit E, de Castro Carpeno J, et al. Outcomes and resource use of non‐small cell lung cancer (NSCLC) patients treated with first‐line platinum‐based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer. 2015;88:215‐222. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7‐34. - PubMed
    1. Huang Y, Zhu L, Guoetal T. Metastatic sites as predictors in advanced NSCLC treated with PD‐1 inhibitors: a systematic review and meta‐analysis. Hum Vaccines Immunother. 2021;17:1278‐1287. - PMC - PubMed

Substances